- Home
- DARE vs MRNS Comparison
DARE vs MRNS Comparison
Compare DARE & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- MRNS
- Stock Information
- Founded
- DARE N/A
- MRNS 2003
- Country
- DARE United States
- MRNS United States
- Employees
- DARE N/A
- MRNS N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- DARE Health Care
- MRNS Health Care
- Exchange
- DARE Nasdaq
- MRNS Nasdaq
- Market Cap
- DARE 31.9M
- MRNS 29.9M
- IPO Year
- DARE N/A
- MRNS 2014
- Fundamental
- Price
- DARE $3.34
- MRNS $0.54
- Analyst Decision
- DARE Strong Buy
- MRNS Buy
- Analyst Count
- DARE 4
- MRNS 12
- Target Price
- DARE $20.33
- MRNS $4.28
- AVG Volume (30 Days)
- DARE 37.5K
- MRNS 3.2M
- Earning Date
- DARE 11-14-2024
- MRNS 03-04-2025
- Dividend Yield
- DARE N/A
- MRNS N/A
- EPS Growth
- DARE N/A
- MRNS N/A
- EPS
- DARE N/A
- MRNS N/A
- Revenue
- DARE $1,881,316.00
- MRNS $31,466,000.00
- Revenue This Year
- DARE N/A
- MRNS $14.97
- Revenue Next Year
- DARE $136.52
- MRNS $57.65
- P/E Ratio
- DARE N/A
- MRNS N/A
- Revenue Growth
- DARE 88.13
- MRNS 1.63
- 52 Week Low
- DARE $2.67
- MRNS $0.22
- 52 Week High
- DARE $7.56
- MRNS $10.50
- Technical
- Relative Strength Index (RSI)
- DARE 52.30
- MRNS 70.29
- Support Level
- DARE $3.03
- MRNS $0.54
- Resistance Level
- DARE $3.38
- MRNS $0.56
- Average True Range (ATR)
- DARE 0.12
- MRNS 0.02
- MACD
- DARE 0.02
- MRNS 0.01
- Stochastic Oscillator
- DARE 88.57
- MRNS 93.71
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.